MDACC Study No:2011-1190 ( NCT No: NCT01489059)
Title:A Phase 1 Dose Escalation Study of BMS-982470 (Recombinant Interleukin-21, rIL-21) in Combination with Ipilimumab in Subjects with Unresectable Stage III or Stage IV Melanoma
Principal Investigator:Patrick Hwu
Treatment Agent:Ipilimumab; Recombinant Interleukin-21
Study Status:Open
Study Description:The goal of this clinical research study is to find the highest tolerable dose
of BMS-982470 that can be combined with ipilimumab and given to patients with
advanced metastatic melanoma.

BMS-982470 is a modified (that is, changed in a laboratory) form of a protein
called interleukin-21 that is normally made by your immune system. This
protein is designed to trigger other cells in your immune system to start
attacking cancer cells.

Ipilimumab is designed to increase the immune system's ability to fight cancer.
Hide details for General InformationGeneral Information

Disease Group:Melanoma
Phase of Study:Phase I
Treatment Agents:Ipilimumab
Recombinant Interleukin-21
Treatment Location:Both at MDACC & and Other Sites
Estimated Length of Stay in Houston:
Supported By:Bristol Myers Squibb
Return Visit:
Home Care:

Hide details for Study Contact InformationStudy Contact Information

Physician Name:Patrick Hwu
Dept:Melanoma Medical Oncology
For Clinical Trial Enrollment:713-792-2921
For General Questions about Clinical Trials:800-392-1611 (in U.S.A.) 713-792-6161 (outside U.S.A.)

Show details for Study Objectives / OutcomesStudy Objectives / Outcomes
Show details for Study Status InformationStudy Status Information
Show details for Enrollment EligibilityEnrollment Eligibility
Show details for Resources and LinksResources and Links
Show details for ResultsResults